sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS

Key facts

Sponsor

Christopher O'Brien, MD

Principal Investigator

Christopher B. O'Brien, MD

University of Miami

Intervention

sPIF(drug)

Enrollment

36 enrolled

Eligibility

18-70 years · FEMALE

Timeline

2014 – 2016

Study locations (2)

• Center for Liver Diseases; University of Miami, Miami, Florida, United States
• Chief Scientist, BIOINCEPT, LLC / Chairman, (SIEP) / Director, Ob&Gyn CAMcare Health Center, Cherry Hill, New Jersey, United States

Collaborators

BioIncept LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Autoimmune hepatitis

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT07378202
  Machine Learning for Prediction of Therapy Response in Autoimmune Hepatitis
  Hannover Medical School
• RECRUITINGPHASE2NCT06381453
  Belimumab in Autoimmune Hepatitis
  University Health Network, Toronto
• RECRUITINGPHASE1NCT06455280
  A Study of SIPLIZUMAB in AILD and LT Patients
  Elizabeth C. Verna
• ENROLLING BY INVITATIONNCT06061341
  TruGraf Liver Gene Expression Serial Test
  Washington University School of Medicine
• RECRUITINGNCT06519162
  Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
  Chungnam National University Hospital
• RECRUITINGNANCT06250309
  Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
  Indiana University
• RECRUITINGNCT05810480
  PredIcting SterOid DepeNdEnt LivEr InjuRy with Polyreactive Immunoglobulin G
  Hannover Medical School
• RECRUITINGNCT06078098
  Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
  University of Milano Bicocca

See all trials for Autoimmune hepatitis →